miR-143 suppresses the proliferation of NSCLC cells by inhibiting the epidermal growth factor receptor

Zhang,Hong‑Bo; Sun,Li‑Chao; Ling,Lan; Cong,Lu‑Hong; Lian,Rui

doi:10.3892/etm.2016.3555

miR-143 suppresses the proliferation of NSCLC cells by inhibiting the epidermal growth factor receptor

Authors:
- Hong‑Bo Zhang
- Li‑Chao Sun
- Lan Ling
- Lu‑Hong Cong
- Rui Lian
View Affiliations

Affiliations: Department of Emergency Medicine, China‑Japan Friendship Hospital, Beijing 100029, P.R. China
Published online on: July 27, 2016 https://doi.org/10.3892/etm.2016.3555
Pages: 1795-1802

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRs) regulate the proliferation and metastasis of numerous cancer cell types. It was previously reported that miR-143 levels were downregulated in non‑small cell lung cancer (NSCLC) tissues and cell lines, and that the migration and invasion of NSCLC cells was inhibited upon suppression of cell proliferation and colony formation by the upregulation of miR‑143. Epidermal growth factor receptor (EGFR), which is a vital factor in the promotion of cancer cell proliferation and has been investigated as a potential focus in cancer therapy, has been reported to be a possible target of miR-143. The present study aimed to investigate the role of miR‑143 in NSCLC using NSCLC cell lines and primary cells from NSCLC patients. NSCLC cells were co‑transfected with EGFR and miR‑143, and the mRNA and protein expression of EGFR were analyzed. Furthermore, the activity of the transfected cancer cells with regard to colony formation, migration, invasion and apoptosis were evaluated. The levels of miR‑143 were decreased in the NSCLC cell lines and primary cells from patients with NSCLC compared with the controls. Following transfection with miR‑143, the ability of NSCLC cells to proliferate, form colonies, migrate and invade was inhibited. Similarly, knockdown of EGFR led to the suppression of NSCLC cell proliferation. The mRNA and protein expression levels of EGFR were significantly reduced following miR‑143 overexpression, and the level of miR‑143 was inversely correlated with that of EGFR in NSCLC cells. The results of the present study demonstrated that miR‑143 was able to suppress NSCLC cell proliferation and invasion by inhibiting the effects of EGFR, suggesting that EGFR may be considered a potential target for NSCLC therapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Youlden DR, Cramb SM and Baade PD: The international epidemiology of lung cancer: Geographical distribution and secular trends. J Thorac Oncol. 3:819–831. 2008. View Article : Google Scholar : PubMed/NCBI
3	Globocan, . 2002, Cancer incidence, mortality and prevalence worldwide. International Agency for Research on Cancer. http://www-dep.iarc.fr/Accessed January 17, 2008. PubMed/NCBI
4	Xu W, Yang G, Xu Y, Zhang Q, Fu Q, Yu J, Yu M, Zhao W, Yang Z, Hu F, et al: The possibility of traditional chinese medicine as maintenance therapy for advanced nonsmall cell lung cancer. Evid Based Complement Alternat Med. 2014:2789172014. View Article : Google Scholar : PubMed/NCBI
5	Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N, Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of non-small cell lung cancer (NSCLC). J Thora Dis Suppl. 4:S389–S396. 2013.
6	Janku F, Stewart DJ and Kurzrock R: Targeted therapy in non-small-cell lung cancer - is it becoming a reality? Nat Rev Clin Oncol. 7:401–414. 2010. View Article : Google Scholar : PubMed/NCBI
7	Toloza EM, Harpole L, Detterbeck F and McCrory DC: Invasive staging of non-small cell lung cancer: A review of the current evidence. Chest. 123(1 Suppl): 157S–166S. 2003. View Article : Google Scholar : PubMed/NCBI
8	Stone E, Allen HA, Saghaie T, Abbott A, Daniel R, Mead RS, Kohonen-Corish M, Plit M and Morgan L: High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer. Intern Med J. 44:1188–1192. 2014. View Article : Google Scholar : PubMed/NCBI
9	Zhou JJ, Zheng S, Sun LF and Zheng L: MicroRNA regulation network in colorectal cancer metastasis. World J Biol Chem. 5:301–307. 2014. View Article : Google Scholar : PubMed/NCBI
10	Ning B, Gao L, Liu RH, Liu Y, Zhang NS and Chen ZY: MicroRNAs in spinal cord injury: Potential roles and therapeutic implications. Int J Biol Sci. 10:997–1006. 2014. View Article : Google Scholar : PubMed/NCBI
11	Rebane A, Runnel T, Aab A, Maslovskaja J, Rückert B, Zimmermann M, Plaas M, Kärner J, Treis A, Pihlap M, et al: MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. J Allergy Clin Immunol. 134:836–847. 2014. View Article : Google Scholar : PubMed/NCBI
12	Wu HH, Lin WC and Tsai KW: Advances in molecular biomarkers for gastric cancer: MiRNAs as emerging novel cancer markers. Expert Rev Mol Med. 16:e12014. View Article : Google Scholar : PubMed/NCBI
13	Schmidt Y, Simunovic F, Strassburg S, Pfeifer D, Stark GB and Finkenzeller G: miR-126 regulates platelet-derived growth factor receptor-α expression and migration of primary human osteoblasts. Biol Chem. 396:61–71. 2015. View Article : Google Scholar : PubMed/NCBI
14	Nagpal N and Kulshreshtha R: MiR-191: An emerging player in disease biology. Front Genet. 5:992014. View Article : Google Scholar : PubMed/NCBI
15	Ibrahim SA, Hassan H and Gotte M: MicroRNA-dependent targeting of the extracellular matrix as a mechanism of regulating cell behavior. Biochim Biophys Acta. 1840:2609–2620. 2014. View Article : Google Scholar : PubMed/NCBI
16	Orang AV and Barzegari A: MicroRNAs in colorectal cancer: From diagnosis to targeted therapy. Asian Pac J Cancer Prev. 15:6989–6999. 2014. View Article : Google Scholar : PubMed/NCBI
17	Adams BD, Kasinski AL and Slack FJ: Aberrant regulation and function of microRNAs in cancer. Curr Biol. 24:R762–R776. 2014. View Article : Google Scholar : PubMed/NCBI
18	Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG and Yang K: MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: Potential biomarkers and therapeutic targets. Cell Prolif. 47:277–286. 2014. View Article : Google Scholar : PubMed/NCBI
19	Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z, Li P, Zhang W, Wu H, Feng N, et al: miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem. 350:207–213. 2011. View Article : Google Scholar : PubMed/NCBI
20	Yu S, Zhang C, Dong FS and Zhang YM: miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. J Cell Biochem. 116:268–276. 2015. View Article : Google Scholar : PubMed/NCBI
21	Fernandez S, Risolino M, Mandia N, Talotta F, Soini Y, Incoronato M, Condorelli G, Banfi S and Verde P: miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene. 34:3240–3250. 2014. View Article : Google Scholar : PubMed/NCBI
22	Zhao X, Liu D, Gong W, Zhao G, Liu L, Yang L and Hou Y: The toll-like receptor 3 ligand, poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143. Stem Cells. 32:521–533. 2014. View Article : Google Scholar : PubMed/NCBI
23	Momeni M, Reza MM, Zainodini N, Hassanshahi G and Arababadi MK: MiR-143 induces expression of AIM2 and ASC in Jurkat cell line. Iran J Immunol. 10:103–109. 2013.PubMed/NCBI
24	Zeng XL, Zhang SY, Zheng JF, Yuan H and Wang Y: Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer. Chin Med J (Engl). 126:4510–4516. 2013.PubMed/NCBI
25	Herbst RS: Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 59:S21–S26. 2004. View Article : Google Scholar
26	Lu Y, Wang Y, Zhang M, Liu L, Li F, Zhang J, Ye M, Zhao H, Zhao J, Yan B and et al: HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth. Oncotarget. 2016.
27	Weiss GJI, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA Jr, Haney J, Helfrich BA, et al: EGFR regulation by microRNA in lung cancer: Correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 19:1053–1059. 2008. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
30	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
31	Phuah NH and Nagoor NH: Regulation of microRNAs by natural agents: New strategies in cancer therapies. Biomed Res Int. 2014:8045102014. View Article : Google Scholar : PubMed/NCBI
32	Bartel D P: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
33	Cai Y, Yu X, Hu S and Yu J: A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 7:147–154. 2009. View Article : Google Scholar : PubMed/NCBI
34	Garajova I, Le Large TY, Frampton AE, Rolfo C, Voortman J and Giovannetti E: Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int. 2014:6784012014. View Article : Google Scholar : PubMed/NCBI
35	Wu XL, Cheng B, Li PY, Huang HJ, Zhao Q, Dan ZL, Tian DA and Zhang P: MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2. World J Gastroenterol. 19:7758–7765. 2013. View Article : Google Scholar : PubMed/NCBI
36	Ferreira AC, Robaina MC, Rezende LM, Severino P and Klumb CE: Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145 and miR-101. Ann Hematol. 93:983–993. 2014.PubMed/NCBI
37	Kopp F, Schnoedt M, Haase R, Wagner E, Roidl A and Ogris M: De-targeting by miR-143 decreases unwanted transgene expression in non-tumorigenic cells. Gene Ther. 20:1104–1109. 2013. View Article : Google Scholar : PubMed/NCBI
38	Ng EK, Li R, Shin VY, Siu JM, Ma ES and Kwong A: MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. Tumour Biol. 35:2591–2598. 2014. View Article : Google Scholar : PubMed/NCBI
39	Blumensatt M, Greulich S, Herzfeld De Wiza D, Mueller H, Maxhera B, Rabelink MJ, Hoeben RC, Akhyari P, Al-Hasani H, Ruige JB, et al: Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143. Cardiovasc Res. 100:201–210. 2013. View Article : Google Scholar : PubMed/NCBI
40	Yang Y, Zhang B, Li R, Liu B and Wang L: EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature. Oncol Lett. 11:3546–3550. 2016.PubMed/NCBI
41	Zhu L, Shi C, Ji C, Xu G, Chen L, Yang L, Fu Z, Cui X, Lu Y and Guo X: FFAs and adipokine-mediated regulation of hsa-miR-143 expression in human adipocytes. Mol Biol Rep. 40:5669–5675. 2013. View Article : Google Scholar : PubMed/NCBI
42	Wang Q, Cai J, Wang J, Xiong C and Zhao J: MiR-143 inhibits EGFR-signaling-dependent osteosarcoma invasion. Tumour Biol. 35:12743–12748. 2014. View Article : Google Scholar : PubMed/NCBI
43	Lu J, Xue L, Jin M and Lyu N: Expression profiling of metastasis-related microRNAs in early esophageal squamous cell carcinoma. Zhonghua Bing Li Xue Za Zhi. 43:313–317. 2014.(In Chinese). PubMed/NCBI
44	Mekenkamp LJ, Tol J, Dijkstra JR, de Krijger I, Vink-Börger ME, van Vliet S, Teerenstra S, Kamping E, Verwiel E, Koopman M, et al: Beyond KRAS mutation status: Influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer. 12:2922012. View Article : Google Scholar : PubMed/NCBI
45	da Cunha Santos G, Shepherd FA and Tsao MS: EGFR mutations and lung cancer. Annu Rev Pathol. 6:49–69. 2011. View Article : Google Scholar
46	Fabian M R, Sonenberg N and Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annual Rev Biochem. 79:351–379. 2010. View Article : Google Scholar
47	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI